Bio-Rad Stock Analysis

BIO -  USA Stock  

USD 628.23  10.93  1.71%

The latest Bio-Rad Laboratories price slide could raise concerns from institutional investors as the firm it trading at a share price of 628.23 on 176,473 in volume. The company executives were unable to exploit market volatilities in December. However, diversifying your overall positions with Bio-Rad Laboratories can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.92. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Continue to Trending Equities.

Bio-Rad Stock Analysis 

 
Refresh
The Bio-Rad Laboratories stock analysis report makes it easy to digest most publicly released information about Bio-Rad Laboratories and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bio-Rad Stock analysis module also helps to analyze the Bio-Rad Laboratories price relationship with some important fundamental indicators such as market cap and management efficiency.

Bio-Rad Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio-Rad Laboratories has Price/Earnings To Growth (PEG) ratio of 2.7. The entity recorded earning per share (EPS) of 220.48. The firm had not issued any dividends in recent years. Bio-Rad Laboratories had 2:1 split on the 8th of March 2002. Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 7800 people. For more info on Bio-Rad Laboratories please contact Norman Schwartz at 510 724-7000 or go to www.bio-rad.com.

Bio-Rad Laboratories Quarterly Cost of Revenue

309.61 MillionShare

Bio-Rad Laboratories Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bio-Rad Laboratories' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio-Rad Laboratories or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bio-Rad Laboratories generated a negative expected return over the last 90 days
Bio-Rad Laboratories is unlikely to experience financial distress in the next 2 years
Bio-Rad Laboratories was previously known as Bio-Rad Laboratories and was traded on New York Stock Exchange under the symbol BIO-B.
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Worldwide Immunohistochemistry Industry to 2028 - Featuring Danaher, Bio-Rad Laboratories and Agilent Technologies Among Others - Yahoo Finance

Bio-Rad Laboratories Upcoming and Recent Events

Earnings reports are used by Bio-Rad Laboratories to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio-Rad Laboratories previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of February 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Bio-Rad Laboratories SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bio-Rad Laboratories prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bio-Rad Laboratories investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bio-Rad Laboratories specific information freely available to individual and institutional investors to make a timely investment decision.
29th of November 2021
Other Events
View
18th of November 2021
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
28th of October 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
4th of October 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
29th of July 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Bio-Rad Laboratories Thematic Classifications

In addition to having Bio-Rad Laboratories stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control IdeaMeasuring and Control
USA Equities from Measuring and Control industry as classified by Fama & French

Bio-Rad Market Capitalization

The company currently falls under 'Large-Cap' category with total capitalization of 19.87 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio-Rad Laboratories's market, we take the total number of its shares issued and multiply it by Bio-Rad Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bio-Rad Profitablity

Bio-Rad Laboratories' profitability indicators refer to fundamental financial ratios that showcase Bio-Rad Laboratories' ability to generate income relative to its revenue or operating costs. If, let's say, Bio-Rad Laboratories is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bio-Rad Laboratories' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bio-Rad Laboratories' profitability requires more research than a typical breakdown of Bio-Rad Laboratories' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 223.47 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 25.47 %, which entails that for every 100 dollars of revenue, it generated 0.25 of operating income.
Last ReportedProjected for 2022
Return on Investment 5.87  6.49 
Return on Average Assets 0.40  0.43 
Return on Average Equity 0.54  0.58 
Return on Invested Capital 0.60  0.65 
Return on Sales 2.23  2.41 

Management Efficiency

The entity has Return on Asset of 2.43 % which means that on every $100 spent on asset, it made $2.43 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 55.13 %, implying that it generated $55.13 on every 100 dollars invested. Bio-Rad Laboratories management efficiency ratios could be used to measure how well bio-rad laboratories manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is expected to rise to 6.49 this year. Return on Average Assets is expected to rise to 0.43 this year. Bio-Rad Laboratories Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.33. Return on Average Assets is expected to rise to 0.43 this year, although the value of Current Assets will most likely fall to about 2.4 B.
Last ReportedProjected for 2022
Book Value per Share 381.68  411.82 
Enterprise Value over EBIT 3.45  3.54 
Enterprise Value over EBITDA 4.01  4.12 
Price to Book Value 2.02  2.09 
Tangible Assets Book Value per Share 482.18  520.24 
Enterprise Value19.8 B21.3 B
Tangible Asset Value14.4 B15.5 B

Technical Drivers

As of the 18th of January 2022, Bio-Rad Laboratories shows the mean deviation of 1.41, and Risk Adjusted Performance of (0.06). Bio-Rad Laboratories technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Bio-Rad Laboratories, which can be compared to its rivals. Please confirm Bio-Rad Laboratories jensen alpha, as well as the relationship between the potential upside and skewness to decide if Bio-Rad Laboratories is priced correctly, providing market reflects its regular price of 628.23 per share. Given that Bio-Rad Laboratories has jensen alpha of (0.18), we suggest you to validate Bio-Rad Laboratories's prevailing market performance to make sure the company can sustain itself at a future point.

Bio-Rad Laboratories Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bio-Rad Laboratories middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bio-Rad Laboratories. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Bio-Rad Laboratories Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio-Rad Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio-Rad Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio-Rad Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Simon May over a week ago via Macroaxis 
Bio-Rad Laboratories exotic insider transaction detected
Dara Wright over a month ago via Macroaxis 
Exercise or conversion by Dara Wright of 502 shares of Bio-Rad Laboratories subject to Rule 16b-3
Alice Schwartz over a month ago via Macroaxis 
Bio-Rad Laboratories exotic insider transaction detected
Annette Tumolo over two months ago via Macroaxis 
Sale by Annette Tumolo of 500 shares of Bio-Rad Laboratories
Timothy Ernst over three months ago via Macroaxis 
Acquisition by Timothy Ernst of 1013 shares of Bio-Rad Laboratories subject to Rule 16b-3
Timothy Ernst over three months ago via Macroaxis 
Payment of 248 shares by Timothy Ernst of Bio-Rad Laboratories subject to Rule 16b-3
Dara Wright over three months ago via Macroaxis 
Payment of 150 shares by Dara Wright of Bio-Rad Laboratories subject to Rule 16b-3
Annette Tumolo over three months ago via Macroaxis 
Sale by Annette Tumolo of 600 shares of Bio-Rad Laboratories
Norman Schwartz over six months ago via Macroaxis 
Exercise or conversion by Norman Schwartz of 2600 shares of Bio-Rad Laboratories subject to Rule 16b-3
Ajit Ramalingam over six months ago via Macroaxis 
Exercise or conversion by Ajit Ramalingam of 276 shares of Bio-Rad Laboratories subject to Rule 16b-3
Andrew Last over six months ago via Macroaxis 
Exercise or conversion by Andrew Last of 1000 shares of Bio-Rad Laboratories subject to Rule 16b-3
Ilan Daskal over six months ago via Macroaxis 
Exercise or conversion by Ilan Daskal of 700 shares of Bio-Rad Laboratories subject to Rule 16b-3

Bio-Rad Laboratories Technical and Predictive Indicators

Bio-Rad Laboratories Forecast Models

Bio-Rad Laboratories time-series forecasting models is one of many Bio-Rad Laboratories' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio-Rad Laboratories' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bio-Rad Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bio-Rad Laboratories stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bio-Rad shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bio-Rad Laboratories. By using and applying Bio-Rad Stock analysis, traders can create a robust methodology for identifying Bio-Rad entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 18.57  14.73 
EBITDA Margin 2.23  2.41 
Gross Margin 0.51  0.50 
Profit Margin 1.72  1.86 
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 7800 people.

Current Bio-Rad Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bio-Rad analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bio-Rad analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
876.67Strong Buy3Odds
Bio-Rad Laboratories current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bio-Rad analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bio-Rad stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bio-Rad Laboratories, talking to its executives and customers, or listening to Bio-Rad conference calls.
Bio-Rad Analyst Advice Details

Bio-Rad Stock Analysis Indicators

Bio-Rad Laboratories stock analysis indicators help investors evaluate how Bio-Rad Laboratories stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bio-Rad Laboratories shares will generate the highest return on investment. By understating and applying Bio-Rad Laboratories stock analysis, traders can identify Bio-Rad Laboratories position entry and exit signals to maximize returns.
Quick Ratio2.70
Fifty Two Week Low545.00
Revenue Growth15.40%
Average Daily Volume Last 10 Day111k
Shares Short Prior Month398.37k
Average Daily Volume In Three Month114.14k
Earnings Growth197.80%
Shares Percent Shares Out1.09%
Earnings Quarterly Growth198.70%
Gross Margins57.83%
Forward Price Earnings49.11
Short Percent Of Float1.53%
Float Shares21.45M
Fifty Two Week High832.70
Fifty Day Average745.41
Enterprise Value To Ebitda26.21
Two Hundred Day Average700.15
Enterprise Value To Revenue6.68
Continue to Trending Equities. Note that the Bio-Rad Laboratories information on this page should be used as a complementary analysis to other Bio-Rad Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Bio-Rad Stock analysis

When running Bio-Rad Laboratories price analysis, check to measure Bio-Rad Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio-Rad Laboratories is operating at the current time. Most of Bio-Rad Laboratories' value examination focuses on studying past and present price action to predict the probability of Bio-Rad Laboratories' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bio-Rad Laboratories' price. Additionally, you may evaluate how the addition of Bio-Rad Laboratories to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Bio-Rad Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio-Rad Laboratories. If investors know Bio-Rad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio-Rad Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio-Rad Laboratories is measured differently than its book value, which is the value of Bio-Rad that is recorded on the company's balance sheet. Investors also form their own opinion of Bio-Rad Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Bio-Rad Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio-Rad Laboratories' market value can be influenced by many factors that don't directly affect Bio-Rad Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio-Rad Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine Bio-Rad Laboratories value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio-Rad Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.